DekaBank Deutsche Girozentrale Has $8.95 Million Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

DekaBank Deutsche Girozentrale lifted its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 1.6% during the third quarter, Holdings Channel.com reports. The firm owned 22,812 shares of the biotechnology company’s stock after acquiring an additional 362 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Axon Enterprise were worth $8,948,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Axon Enterprise by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after buying an additional 212,401 shares during the last quarter. Motley Fool Asset Management LLC boosted its holdings in Axon Enterprise by 238.7% in the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after acquiring an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. increased its position in Axon Enterprise by 44.0% during the 2nd quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock valued at $110,546,000 after purchasing an additional 114,800 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Axon Enterprise by 13.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock worth $108,496,000 after purchasing an additional 45,049 shares during the last quarter. Finally, Thrivent Financial for Lutherans lifted its position in shares of Axon Enterprise by 1.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 270,430 shares of the biotechnology company’s stock worth $79,571,000 after purchasing an additional 4,365 shares during the period. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Down 1.1 %

Shares of Axon Enterprise stock opened at $439.00 on Thursday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The stock has a fifty day simple moving average of $400.22 and a 200 day simple moving average of $339.14. Axon Enterprise, Inc. has a 12-month low of $199.50 and a 12-month high of $455.17. The company has a market capitalization of $33.13 billion, a P/E ratio of 128.36, a price-to-earnings-growth ratio of 11.91 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. During the same quarter in the prior year, the company posted $0.80 earnings per share. The firm’s revenue for the quarter was up 34.5% on a year-over-year basis. On average, sell-side analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In related news, Director Julie A. Cullivan sold 900 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $353.53, for a total transaction of $318,177.00. Following the completion of the sale, the director now directly owns 3,653 shares of the company’s stock, valued at approximately $1,291,445.09. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Patrick W. Smith sold 80,300 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $371.78, for a total value of $29,853,934.00. Following the transaction, the chief executive officer now directly owns 3,015,366 shares of the company’s stock, valued at approximately $1,121,052,771.48. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Julie A. Cullivan sold 900 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $353.53, for a total transaction of $318,177.00. Following the sale, the director now owns 3,653 shares of the company’s stock, valued at $1,291,445.09. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 371,172 shares of company stock worth $137,000,162 in the last 90 days. Insiders own 6.10% of the company’s stock.

Analyst Ratings Changes

AXON has been the subject of a number of analyst reports. Robert W. Baird lifted their target price on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Bank of America started coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price on the stock. The Goldman Sachs Group boosted their price target on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Jefferies Financial Group initiated coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective for the company. Finally, Barclays increased their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $382.85.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.